All articles tagged with #mflusiva
Moderna’s mFlusiva, the first mRNA-based flu vaccine, is now available at over 13,000 US locations for adults 50 and older. While it offers roughly 27-30% better protection than traditional shots, availability is limited and insurance coverage for those under 65 remains uncertain.
As fall arrives, health officials urge immediate flu vaccination to ensure protection before the winter peak. The 2026-27 season features updated trivalent vaccines targeting the H3N2 subclade K and a new mRNA option for adults over 50. While immunity takes two weeks to develop, experts warn that waiting until November may leave individuals vulnerable during the December-February surge.
Moderna’s mFlusiva is the first mRNA-based flu shot and is now available in the US for adults 50 and older (50–64 traditional, 65+ accelerated approvals). In Phase 3 it was about 27% more effective than a standard flu shot; it uses mRNA and can be produced in 2–3 months, but it does not protect against COVID. Younger than 50 can’t get it this season. Price is about $171 per dose without insurance, with coverage varying by insurer, and it’s rolling out to CVS/Walgreens as stock permits ahead of the October vaccination window.
The FDA approved Moderna’s mRNA flu vaccine, mFLUSIVA, for adults 50–64 and gave accelerated approval for adults 65+, with the potential to rapidly reformulate to match circulating influenza strains. In trials, it showed a 26.6% relative reduction in lab-confirmed flu versus standard vaccines and was generally well tolerated, though side effects were more common. Regulators in the EU, Canada, and Australia are reviewing similar uses, and a Phase IV trial is planned to assess efficacy against an enhanced 65+ vaccine. Separately, Europe has approved a combined influenza and COVID-19 mRNA vaccine (mCombriax). Experts say the technology could improve responsiveness to evolving flu strains and ease manufacturing bottlenecks, but real-world effectiveness will determine its ultimate impact.
FDA-approved Moderna’s mFlusiva, an mRNA flu vaccine, for adults 50–64 (full approval) and 65+ (accelerated approval) after trials showed about 27% higher effectiveness than the standard flu shot; the vaccine could be updated quickly to address circulating strains. It’s expected to be available this fall, though insurance coverage remains unclear. Side effects may be stronger than with traditional vaccines but are generally mild. Health experts say to get whichever flu vaccine is available to protect yourself early in the season.
The FDA has approved Moderna's mRNA seasonal flu vaccine, mFlusiva (mRNA-1010), for adults 50 and older after initially declining to review the application; Phase 3 data show the vaccine is superior to standard vaccines in preventing influenza-like illness in adults 50+, with more mild adverse events, and approvals cover ages 50-64 (and accelerated approval for those 65 and older).